{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-335267","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2025-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.700072+00:00","generated_at":"2026-05-16T12:08:00.280706+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SAB Biotherapeutics establishes new $75M ATM equity program via UBS, terminates prior $20M ATM","bullets":["Entered sales agreement with UBS Securities for at-the-market offering of common stock up to $75 million aggregate offering price.","Prior $20M ATM program with Cantor Fitzgerald terminated effective Dec 17, 2025; Cantor waived 60-day restriction.","Net proceeds intended for pipeline development, general corporate and working capital purposes.","Agent fee up to 3% of gross proceeds; program may be terminated by either party on 10 days' notice."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-335267","json":"https://secwatch.observer/filing/0001193125-25-335267.json","markdown":"https://secwatch.observer/filing/0001193125-25-335267.md","text":"https://secwatch.observer/filing/0001193125-25-335267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525335267/0001193125-25-335267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000119312525335267/sabs-20251229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:08:00.280706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}